Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1931 1
1959 2
1960 3
1961 2
1962 1
1963 6
1964 1
1965 1
1966 2
1967 2
1968 6
1969 2
1970 4
1971 3
1972 4
1973 4
1974 1
1975 6
1976 2
1977 1
1978 3
1979 1
1980 3
1981 1
1982 9
1983 5
1984 4
1985 4
1986 5
1987 6
1988 3
1989 6
1990 5
1991 6
1992 3
1993 4
1994 3
1995 5
1996 9
1997 6
1998 4
1999 3
2000 4
2001 12
2002 5
2003 9
2004 8
2005 6
2006 5
2007 9
2008 3
2009 9
2010 3
2011 7
2012 7
2013 8
2014 7
2015 4
2016 4
2017 7
2018 12
2019 16
2020 11
2021 15
2022 21
2023 15
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

350 results

Results by year

Filters applied: . Clear all
Page 1
Selective Inhibition of NaV1.8 with VX-548 for Acute Pain.
Jones J, Correll DJ, Lechner SM, Jazic I, Miao X, Shaw D, Simard C, Osteen JD, Hare B, Beaton A, Bertoch T, Buvanendran A, Habib AS, Pizzi LJ, Pollak RA, Weiner SG, Bozic C, Negulescu P, White PF; VX21-548-101 and VX21-548-102 Trial Groups. Jones J, et al. Among authors: simard c. N Engl J Med. 2023 Aug 3;389(5):393-405. doi: 10.1056/NEJMoa2209870. N Engl J Med. 2023. PMID: 37530822 Clinical Trial.
Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.
Middleton PG, Mall MA, Dřevínek P, Lands LC, McKone EF, Polineni D, Ramsey BW, Taylor-Cousar JL, Tullis E, Vermeulen F, Marigowda G, McKee CM, Moskowitz SM, Nair N, Savage J, Simard C, Tian S, Waltz D, Xuan F, Rowe SM, Jain R; VX17-445-102 Study Group. Middleton PG, et al. Among authors: simard c. N Engl J Med. 2019 Nov 7;381(19):1809-1819. doi: 10.1056/NEJMoa1908639. Epub 2019 Oct 31. N Engl J Med. 2019. PMID: 31697873 Free PMC article. Clinical Trial.
Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia.
Locatelli F, Lang P, Wall D, Meisel R, Corbacioglu S, Li AM, de la Fuente J, Shah AJ, Carpenter B, Kwiatkowski JL, Mapara M, Liem RI, Cappellini MD, Algeri M, Kattamis A, Sheth S, Grupp S, Handgretinger R, Kohli P, Shi D, Ross L, Bobruff Y, Simard C, Zhang L, Morrow PK, Hobbs WE, Frangoul H; CLIMB THAL-111 Study Group. Locatelli F, et al. Among authors: simard c. N Engl J Med. 2024 May 9;390(18):1663-1676. doi: 10.1056/NEJMoa2309673. Epub 2024 Apr 24. N Engl J Med. 2024. PMID: 38657265 Clinical Trial.
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.
Heijerman HGM, McKone EF, Downey DG, Van Braeckel E, Rowe SM, Tullis E, Mall MA, Welter JJ, Ramsey BW, McKee CM, Marigowda G, Moskowitz SM, Waltz D, Sosnay PR, Simard C, Ahluwalia N, Xuan F, Zhang Y, Taylor-Cousar JL, McCoy KS; VX17-445-103 Trial Group. Heijerman HGM, et al. Among authors: simard c. Lancet. 2019 Nov 23;394(10212):1940-1948. doi: 10.1016/S0140-6736(19)32597-8. Epub 2019 Oct 31. Lancet. 2019. PMID: 31679946 Free PMC article. Clinical Trial.
Exagamglogene Autotemcel for Severe Sickle Cell Disease.
Frangoul H, Locatelli F, Sharma A, Bhatia M, Mapara M, Molinari L, Wall D, Liem RI, Telfer P, Shah AJ, Cavazzana M, Corbacioglu S, Rondelli D, Meisel R, Dedeken L, Lobitz S, de Montalembert M, Steinberg MH, Walters MC, Eckrich MJ, Imren S, Bower L, Simard C, Zhou W, Xuan F, Morrow PK, Hobbs WE, Grupp SA; CLIMB SCD-121 Study Group. Frangoul H, et al. Among authors: simard c. N Engl J Med. 2024 May 9;390(18):1649-1662. doi: 10.1056/NEJMoa2309676. Epub 2024 Apr 24. N Engl J Med. 2024. PMID: 38661449 Clinical Trial.
VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
Keating D, Marigowda G, Burr L, Daines C, Mall MA, McKone EF, Ramsey BW, Rowe SM, Sass LA, Tullis E, McKee CM, Moskowitz SM, Robertson S, Savage J, Simard C, Van Goor F, Waltz D, Xuan F, Young T, Taylor-Cousar JL; VX16-445-001 Study Group. Keating D, et al. Among authors: simard c. N Engl J Med. 2018 Oct 25;379(17):1612-1620. doi: 10.1056/NEJMoa1807120. Epub 2018 Oct 18. N Engl J Med. 2018. PMID: 30334692 Free PMC article. Clinical Trial.
TRPM4 contribution in mouse uterine contractions.
Fouchet A, Bangando HM, Aize M, Simard C, Guinamard R. Fouchet A, et al. Among authors: simard c. Reproduction. 2023 Jun 19;166(2):77-87. doi: 10.1530/REP-22-0484. Print 2023 Aug 1. Reproduction. 2023. PMID: 37204208
TRPM4 in cardiac electrical activity.
Guinamard R, Bouvagnet P, Hof T, Liu H, Simard C, Sallé L. Guinamard R, et al. Among authors: simard c. Cardiovasc Res. 2015 Oct 1;108(1):21-30. doi: 10.1093/cvr/cvv213. Epub 2015 Aug 13. Cardiovasc Res. 2015. PMID: 26272755 Review.
Factor XI Inhibitors: Potential Role in End-Stage Kidney Disease.
Ades M, Simard C, Vanassche T, Verhamme P, Eikelboom J, Mavrakanas TA. Ades M, et al. Among authors: simard c. Semin Nephrol. 2023 Nov;43(6):151484. doi: 10.1016/j.semnephrol.2023.151484. Epub 2024 Jan 24. Semin Nephrol. 2023. PMID: 38272779 Review.
Overview of Cardiac Arrhythmias and Treatment Strategies.
Kingma J, Simard C, Drolet B. Kingma J, et al. Among authors: simard c. Pharmaceuticals (Basel). 2023 Jun 6;16(6):844. doi: 10.3390/ph16060844. Pharmaceuticals (Basel). 2023. PMID: 37375791 Free PMC article. Review.
350 results